Fragment 176-191 and its Uses in Fat Loss

by | Apr 19, 2021 | Research

Fragment 176-191 is a synthetic peptide fragment of human growth hormone (HGH). It spans from the 176th to the 191st amino acid residues of the human growth hormone. The fragment comprises an additional tyrosine amino acid residue apart from amino acids 177-191. Research has shown that Frag 176-191, a synthetic Growth Hormone Releasing Hormone (GHRH) agonist, is a strong catalyst for the catabolism of adipocytes. Interestingly, in 1959, human growth hormone was first associated with fat metabolism. Fragment 176-191 and Fat Reduction.

Fragment 176-191 exhibits a unique property to stimulate the metabolism of adipose tissue. Research findings reveal that the molecule AOD9604 is more effective in triggering the burning of fat than AOD9401, which preceded it. It follows the same mechanistic pathway for a fat breakdown as HGH. It also inhibits the conversion of food rich in fat into body fat. Clinical research and laboratory findings have led to the above observations concerning the functional capabilities of the peptide fragment.

Studies have suggested that Fragment 176-191 in mice has successfully reduced the fat burden in the treated animals through induction of weight loss. The precise reason for this effect is not yet completely understood. However, scientists opine that the binding of the peptide to beta(3)-adrenergic receptors on the surface of white adipose tissues triggers the fat metabolism process. These receptors are well known to be associated with the metabolism of fat in the body. The peptide binding to the cognate receptors induces downstream signaling for mobilizing the stored fat cells to a usable state by increasing the rate of metabolism. Interestingly, mice that genetically lack β-3-adrenergic receptors also have undergone fat loss, possibly through apoptosis of the white adipose tissues. Recent findings have shown that the peptide can also decrease body fat in the mid-abdomen of research subjects who have an average build or are overweight or obese.

Fragment 176-191 and Cardiac Disease

Frag 176-191 can potentially improve cardiac health by mobilizing fat and reducing obesity. Cardiac disease is known to be caused by obesity. These pathways are independent of β-3-adrenergic receptors and may contribute to improving general metabolism and cardiac health.

Joint Pain and Function

Studies involving Frag 176-191 have demonstrated that it can help to improve cartilage growth. Directly introducing the peptide into arthritic joints in rats improves pain management and decreases movement disability.  Clinical examination and microscopic cartilage structure analysis in the affected joints have shown positive results upon Fragment 176-191 treatment of osteoarthritis in rats. This highlights that applying this peptide can be beneficial in both the prevention and treatment of osteoarthritis.



Disclaimer: The products mentioned are not for human or animal consumption. All the information shared in this article is for educational purposes only.